At a glance
| US product | Zilbrysq |
|---|---|
| Target | Complement C5 |
| Approved population | Adults with AChR-antibody-positive generalized myasthenia gravis |
| Route | Subcutaneous injection |
| US safety program | Zilbrysq REMS |
| Boxed warning | Serious meningococcal infection |
Overview
In acetylcholine-receptor antibody-positive myasthenia gravis, complement contributes to damage where nerves communicate with muscles. Zilucoplan targets that process through a peptide delivered subcutaneously under the brand Zilbrysq. Its US indication is specifically adult generalized disease with these antibodies; this should not be broadened to every form of muscle weakness or every myasthenia antibody subtype. Clinical studies measured changes in daily function and weakness scores. Complement inhibition can improve disease activity while leaving the underlying tendency to form pathogenic antibodies intact, so the medicine is part of continuing specialist management rather than a permanent cure.
How it works
Zilucoplan binds complement protein C5 and inhibits its cleavage into C5a and C5b. It also interferes with the terminal complement assembly process, reducing formation of membrane attack complexes. In antibody-positive myasthenia gravis, this helps protect the postsynaptic membrane. The same terminal complement machinery is important for defense against Neisseria bacteria, creating a mechanistic link between therapeutic benefit and serious infection risk.
Which myasthenia gravis patients were studied?
The approved population is adults with generalized disease who test positive for acetylcholine-receptor antibodies. Benefit should not be assumed for isolated ocular disease, antibody-negative weakness, or another neuromuscular diagnosis. Disease assessment includes function, respiratory or bulbar symptoms, existing therapies, and infection risk.
Supporting sources [1]
The RAISE trial
The randomized RAISE trial compared zilucoplan with placebo over 12 weeks and found improvement in the Myasthenia Gravis Activities of Daily Living score, with supportive changes in other weakness measures. This supports symptomatic and functional efficacy in the studied population. Trial improvement does not mean that treatment eliminates all crisis risk or cures autoimmunity.
Infections and pancreatic events
Life-threatening meningococcal disease can occur despite vaccination. The label requires a risk-management program and appropriate immunization precautions; other encapsulated bacterial infections are also a concern. Pancreatitis and pancreatic cysts have been reported. Injection-site reactions, upper respiratory infections, and diarrhea occurred in trials and require context alongside serious risks.
Supporting sources [1]
Does vaccination remove the infection risk?
No. Vaccination is an important precaution but does not fully restore terminal complement defense. Patients still need education about urgent symptoms and access to rapid assessment. The regulatory safety requirements apply to the approved medicine and do not validate research peptides sold under the same chemical name.
Supporting sources [1]
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Synthetic macrocyclic peptide complement C5 inhibitor.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Zilbrysq — US prescribing information ↗Regulatory source · Checked 2026-10-27
- Safety and efficacy of zilucoplan in generalized myasthenia gravis (RAISE): a randomized phase 3 study ↗Original research · Checked 2026-10-27